OUD in Special Populations CME
How to participate in the activity: Visit https://illinoisadvance.uic.edu/schedule-a-visit/
Target Audience: Physicians, Physician Assistants, and Nurse Practitioners
Fee: Free
Expiration Date: March 10, 2026
Number of Credit Hours: 0.5 contact hours (0.05 CEUs)
Type of Activity: Knowledge-based
Learning Objectives:
- Discuss the special populations with OUD that may have unique treatment needs when treating this disease
- Discuss the current recommended treatment for pregnant and breastfeeding women with OUD
- Discuss the current recommended treatment of children and adolescents with OUD
Speaker(s): For a list of potential speakers please visit https://illinoisadvance.com/about-us/meet-team/
Disclosure(s):
The speakers, planning committee members, and reviewers who contributed to this program have no relevant financial conflicts of interest to disclose unless noted below.
- Speaker, Dr. Chintan Patel has stock ownership with companies: Abbvie, Dynavax Technologies Corp, Esperion Therapeutics Inc, Gilead Sciences Inc, Glasko Smith Kline, Haleon, EOM Pharmaceuticals, Lisata Therapeutics Inc, Novavax Inc, Pfizer Inc, Protalix Biotherapeutics Inc, and PuImatrix Inc.
- Speaker, Dr. Thomas Dorn has stock ownership with companies Inovio Pharmaceuticals, Eli Lily, and Lexicon Pharmaceuticals.
- Speaker, Dr. Sajitha Purathur has stock ownership with Pfizer.
- Speaker, Dr. Chirag Rathod has stock ownership with MindMed.
- Speaker, Dr. Stewart Chung has stock ownership with Silo Pharmaceutical.
All relevant financial relationships listed for the above speakers have been mitigated.